Free Trial
NASDAQ:SMMT

Summit Therapeutics Q2 2025 Earnings Report

Summit Therapeutics logo
$28.66 +0.59 (+2.10%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$28.65 -0.01 (-0.03%)
As of 08/8/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Summit Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Summit Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
9:30AM ET

Conference Call Resources

Summit Therapeutics Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Summit Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email.

About Summit Therapeutics

Summit Therapeutics (NASDAQ:SMMT) Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

View Summit Therapeutics Profile

More Earnings Resources from MarketBeat